Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: J Immunol. 2022 Apr 8;208(9):2085–2097. doi: 10.4049/jimmunol.2100926

Figure 1: Induction of allergic asthma with OVA and LPS treatment is dependent on TLR4 expression.

Figure 1:

WT, TLR4-SNP, or TLR4−/− mice were treated with either Ovalbumin (OVA), Lipopolysaccharide (LPS), or a combination of both according to the timeline (A). Groups of mice were initially treated with 100 μg of OVA or OVA + 0.1 μg of LPS for 3 days, and then all groups were treated with 100 μg of OVA for 4 days prior to euthanasia on day +21. Lungs were lavaged with 1 mL of PBS to obtain Bronchoalveolar Lavage (BAL); this was used to prepare cytospins followed by differential cell counting to determine the percentages of eosinophils, macrophages, neutrophils, and lymphocytes in each treatment group. (B) is a representative summation of 1 individual trial to describe the cell type composition and percentages of BALF. (C) shows total BALF cell counts from 3 independent trials, (D-G) shows the individual total cell number (D, E) and individual cell percentage (F, G) of eosinophils and macrophages of individual mice from 3 independent trials (n=4–5/treatment group/trial for OVA-treated groups, n=5/treatment group/trial for OVA-LPS-treated groups) with each point representing an individual mouse. Open circles designate females and closed circles designate males. All data was analyzed by 2-way ANOVA with Tukey’s Multiple Comparisons Test: *, P<0.05; **, P<0.005; ***, P<0.0005; ****, P<0.0001. Error bars represent mean ± SEM.